In the female athletic community, there are several endogenous and exogenous
variables that influence the status of the hypothalamus-pituitary-ovarian axis
and serum sex steroid hormones concentrations (e. g.,
17β-estradiol, progesterone, androgens) and their effects. Moreover,
female athletes with different sex chromosome abnormalities exist
(e. g., 46XX, 46XY, and mosaicism). Due to the high variability of sex
steroid hormones serum concentrations and responsiveness, female athletes may
have different intra- and inter-individual biological and functional
characteristics, health conditions, and sports-related health risks that can
influence sports performance and eligibility. Consequently, biological,
functional, and/or sex steroid differences may exist in the same and in
between 46XX female athletes (e. g., ovarian rhythms, treated or
untreated hypogonadism and hyperandrogenism), between 46XX and 46XY female
athletes (e. g., treated or untreated hyperandrogenism/disorders
of sexual differentiation), and between transgender women and eugonadal
cisgender athletes. From a healthcare perspective, dedicated physicians need
awareness, knowledge, and an understanding of sex steroid hormones’
variability and related health concerns in female athletes to support
physiologically healthy, safe, fair, and inclusive sports participation. In this
narrative overview, we focus on the main clinical relationships between
hypothalamus-pituitary-ovarian axis function, endogenous sex steroids and health
status, health risks, and sports performance in the heterogeneous female
athletic community.